Preclinical data have shown that combining a KrasG12C inhibitor with an EGFR antibody or an SHP2 inhibitor – two proteins active upstream of RAS – diminished tumor growth in KrasG12C‐mutant cancers [73, 76]. Here, EGFR is linked to neoplasm.